Related Experiment Video
Updated: May 21, 2026
08:52
Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
Published on: February 5, 2021
Medical therapy and mucosal healing
Marc Ferrante1, Gert Van Assche
1Department of Gastroenterology, University Hospital Leuven, Herestraat 49, Leuven, Belgium. marc.ferrante@uzleuven.be
Current Drug Targets
|June 6, 2012
Summary
Mucosal healing is key for ulcerative colitis treatment and emerging for Crohn's disease. Anti-TNF agents show promise in healing Crohn's ulcerations, potentially reducing relapses and hospitalizations.
Area of Science:
- Gastroenterology and Hepatology
- Inflammatory Bowel Disease (IBD) Research
- Clinical Trial Endpoints
Background:
- Mucosal healing is a standard efficacy measure in ulcerative colitis.
- The concept of mucosal healing is increasingly recognized in Crohn's disease clinical trials, particularly with biologic therapies.
- Traditional treatments like systemic steroids lack reliable mucosal healing induction in Crohn's disease.
Purpose of the Study:
- To review the role and evidence of mucosal healing in Crohn's disease.
- To assess the efficacy of different therapeutic classes in achieving mucosal healing.
- To provide guidance on incorporating mucosal healing assessment into clinical practice for IBD.
Main Methods:
- Review of clinical trial data and scientific literature.
- Analysis of evidence for purine analogues and anti-TNF agents in Crohn's disease.
- Evaluation of the clinical significance of mucosal healing in Crohn's disease.
Main Results:
- Purine analogues and anti-TNF agents demonstrate potential for healing mucosal ulcerations in Crohn's disease.
- Evidence supports mucosal healing for infliximab, adalimumab, and certolizumab pegol in Crohn's disease.
- For infliximab, mucosal healing correlates with reduced clinical relapses, hospitalizations, and surgeries.
Conclusions:
- Mucosal healing is an emerging and important therapeutic goal in Crohn's disease.
- Anti-TNF agents are effective in inducing mucosal healing, with clinical benefits.
- Assessing mucosal healing is valuable in clinical practice for IBD patients with persistent symptoms or considering treatment changes.
Related Concept Videos
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.